Amplo Biotechnology Closes Series Seed Financing To Advance Gene Therapies For The Treatment Of Neuromuscular Junction Disorders

Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for diseases affecting the neuromuscular junction, today announced the successful closing of an undisclosed Series Seed financing. The Seed round was led by BioBrit, LLC., joined by Casdin Capital, SeedFolio and small group of sophisticated, biotech angel investors. In conjunction with the financing, Dan Bradbury (BioBrit, LLC.) has been appointed Chair of the Board. It was also announced that Amplo was awarded a NIH Fast-Track Phase I/II SBIR grant for the development of AMP-101 gene therapy.